168 related articles for article (PubMed ID: 35902731)
1. ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
Schönfeld L; Rinke J; Hinze A; Nagel SN; Schäfer V; Schenk T; Fabisch C; Brümmendorf TH; Burchert A; le Coutre P; Krause SW; Saussele S; Safizadeh F; Pfirrmann M; Hochhaus A; Ernst T
Leukemia; 2022 Sep; 36(9):2242-2249. PubMed ID: 35902731
[TBL] [Abstract][Full Text] [Related]
2. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.
Schmidt M; Rinke J; Schäfer V; Schnittger S; Kohlmann A; Obstfelder E; Kunert C; Ziermann J; Winkelmann N; Eigendorff E; Haferlach T; Haferlach C; Hochhaus A; Ernst T
Leukemia; 2014 Dec; 28(12):2292-9. PubMed ID: 25212276
[TBL] [Abstract][Full Text] [Related]
3. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia.
Bidikian A; Kantarjian H; Jabbour E; Short NJ; Patel K; Ravandi F; Sasaki K; Issa GC
Blood Cancer J; 2022 Oct; 12(10):144. PubMed ID: 36307398
[TBL] [Abstract][Full Text] [Related]
5. Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients.
Park H; Kim I; Kim HJ; Shin DY; Lee SY; Kwon OH; Kim DY; Lee KH; Ahn JS; Park J; Sohn SK; Lee JO; Cheong JW; Kim KH; Kim HG; Kim H; Lee YJ; Nam SH; Do YR; Park SG; Park SK; Bae SH; Song HH; Oh D; Jung CW; Park S
Leuk Res; 2021 Dec; 111():106728. PubMed ID: 34673444
[TBL] [Abstract][Full Text] [Related]
6. Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients.
Rafiq Mohammed A; Assad D; Rostami G; Hamid M
Gene; 2023 Nov; 886():147776. PubMed ID: 37689224
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
[TBL] [Abstract][Full Text] [Related]
8. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
9. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
10. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akkaynak DZ; Dag IM; Ilhan O
Expert Opin Pharmacother; 2016 Oct; 17(14):1851-8. PubMed ID: 27501474
[TBL] [Abstract][Full Text] [Related]
11. Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.
Togasaki E; Takeda J; Yoshida K; Shiozawa Y; Takeuchi M; Oshima M; Saraya A; Iwama A; Yokote K; Sakaida E; Hirase C; Takeshita A; Imai K; Okumura H; Morishita Y; Usui N; Takahashi N; Fujisawa S; Shiraishi Y; Chiba K; Tanaka H; Kiyoi H; Ohnishi K; Ohtake S; Asou N; Kobayashi Y; Miyazaki Y; Miyano S; Ogawa S; Matsumura I; Nakaseko C; Naoe T
Blood Cancer J; 2017 Apr; 7(4):e559. PubMed ID: 28452984
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
Soverini S; de Benedittis C; Mancini M; Martinelli G
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S120-8. PubMed ID: 26297264
[TBL] [Abstract][Full Text] [Related]
13. Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.
Kim T; Tyndel MS; Zhang Z; Ahn J; Choi S; Szardenings M; Lipton JH; Kim HJ; Kim Dong Hwan D
Leuk Res; 2017 Aug; 59():142-148. PubMed ID: 28667884
[TBL] [Abstract][Full Text] [Related]
14. CML - Not only BCR-ABL1 matters.
Rinke J; Hochhaus A; Ernst T
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101194. PubMed ID: 33038988
[TBL] [Abstract][Full Text] [Related]
15. A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation.
Imataki O; Ishida T; Kubo H; Uemura M; Nanya Y; Kawakami K; Ogawa S; Kadowaki N
Case Rep Oncol; 2020; 13(1):449-455. PubMed ID: 32399015
[TBL] [Abstract][Full Text] [Related]
16. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia].
Jiang H; Chen SS; Jiang B; Jiang Q; Qin YZ; Lai YY; Liu YR; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):123-6. PubMed ID: 22730663
[TBL] [Abstract][Full Text] [Related]
18. ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia.
Valikhani A; Poopak B; Ferdowsi S; Azizi Tabesh G; Ghaffari SH; Saraf Kazeruoni E; Rezaei N; Farshchi A; Amirizadeh N
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e41-e47. PubMed ID: 27640403
[TBL] [Abstract][Full Text] [Related]
19. [Nilotinib as a second-line treatment for chronic myeloid leukemia].
Yamauchi T; Ueda T
Gan To Kagaku Ryoho; 2011 Jun; 38(6):911-5. PubMed ID: 21677481
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
